Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adoptive T Cell Therapy With DC/AML Fusion Vaccine, Decitabine, and Venetoclax in AML
NCT07374029Phase 1Recruiting
- Sponsor
- David Avigan
- Start
- Feb 2026
- Primary completion
- Oct 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous dendritic cell-tumor fusion vaccine in acute myeloid leukemia (AML) (2 arms), sponsored by David Avigan. Primary endpoints: Successful Manufacture and Administration Rate of Vaccine-Educated T Cells at 28 weeks, Maximum Tolerated Dose of Vaccine-Educated T Cells at 56 Days and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07374029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374029.